Pharmaceutical Industry – Sanofi strengthens its mRNA activity – Economy

The French pharmaceutical company Sanofi wants to advance research into mRNA vaccines and buy the American biotechnology company Translate Bio. Sanofi is offering $ 3.2 billion in cash or $ 38 per share, as the company announced on Tuesday. The boards of directors of both companies have already approved the purchase. With Translate Bio, Sanofi could advance its goals in mRNA technology and vaccine development as therapeutics, said Sanofi boss Paul Hudson. Following the success of Biontech / Pfizer’s mRNA-based Covid-19 vaccine and Moderna’s vaccine, the technology has become the focus of pharmaceutical companies. Sanofi has a long-standing commitment to the development of vaccines and drugs based on mRNA technology. The French want to bring at least six vaccines to clinical development by 2025. Translate Bio was founded in 2016 and has not yet launched any drug. An mRNA-based therapeutic agent for cystic fibrosis, a metabolic disease, is in clinical studies.

Related Articles

Back to top button